Immunization, Mayo Clinic and Specialty Pharmacies

TikTok Videos on IBD Provide Low Quality Information

Drug Topics

JUNE 6, 2025

Additionally, pharmacists can make sure that patients have updated immunizations, especially for patients who are on immunosuppressive therapy. Mayo Clinic. Disease management—such as medication, surgery, and diet—was prevalent in 32% of videos. They can provide support for adherence, monitor safety, and educate patients.

FDA

FDA Immunization Mayo Clinic Dosage

Pharmacist-Led Interventions Show Promise in Improving COPD Outcomes

Drug Topics

JULY 17, 2025

Mayo Clinic Staff. Mayo Clinic. link] Newsletter Pharmacy practice is always changing. The impact of pharmacist-led interventions on the treatment of COPD patients. Med Princ Pract. 2025; [link] 2. What is COPD? National Heart, Lung, and Blood Institute. November 8, 2024. Accessed July 17, 2025. August 30, 2024.

Specialty Pharmacies

Specialty Pharmacies Mayo Clinic Patient Care Compounding

Efficiency, Education, and Evolution: What’s Next for Pharmacy Practice?

Pharmacy Times

JUNE 24, 2025

In an interview with Pharmacy Times at the 2025 Oncology Pharmacists Connect (OPC) meeting, Scott Soefje, PharmD, MBA, BCOP, director of pharmacy at Mayo Clinic, focused on the evolving role of pharmacists in healthcare, highlighting their increasing presence in outpatient settings to enhance efficiency and patient care.

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Hospitals

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Pharmacy Times

JUNE 16, 2025

Mayo Clinic. Pharmacy Times. RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years. News release. June 6, 2025. Accessed June 16, 2025. Atopic Dermatitis. News release.

Compounding Pharmacies

Compounding Pharmacies FDA Immunization Mayo Clinic

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

JUNE 23, 2025

This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.

FDA

FDA Compounding Pharmacies Dosage Hospitals

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

JUNE 20, 2025

Pharmacy Times : As immunotherapies expand into the solid tumor space, clinicians are reporting cases of ICANS and CRS. Have you observed these immune-related toxicities in your practice, and if so, how are they being managed? All patients should have immunotherapy first. It was approved last year.

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Hospitals

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Pharmacy Times

JULY 7, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Sirtex Medical’s SIR-Spheres ® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma.

FDA

FDA Compounding Pharmacies Immunization Mayo Clinic

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacy Times

JUNE 9, 2025

Still, confusion remains over the role of pharmacy and therapeutics (P&T) committees in this process. Tichy, PharmD, MBA, vice chair of pharmacy formulary for Mayo Clinic, explained. This governance issue is a very hot topic,” Eric M.

Compounding Pharmacies

Compounding Pharmacies FDA Hospitals Immunization

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

JULY 9, 2025

Mayo Clinic. Pharmacy Times. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease. Eli Lilly and Company. News release. July 9, 2025. Accessed July 9, 2025. Alzheimer’s Disease. News release. November 8, 2024. Accessed July 9, 2025. link] Gallagher A.

Labelling

Labelling FDA Compounding Pharmacies Independent Pharmacies

Dual-Antigen Targeting in Myeloma: Improved Responses in Extramedullary Disease

Pharmacy Times

JUNE 26, 2025

In an interview with Pharmacy Times , Shaji Kumar, MD, consultant and research chair of the Division of Hematology in the Department of Internal Medicine at Mayo Clinic, discussed emerging data from the phase 2 RedirecTT-1 study (NCT04586426).

Compounding Pharmacies

Compounding Pharmacies Vaccines Immunization Mayo Clinic

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Pharmacy Times

JULY 14, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. News release. July 9, 2025. Accessed July 10, 2025. Prostate Cancer. News release. February 20, 2025.

FDA

FDA Compounding Pharmacies Compounding Immunization

Tirzepatide, Hormone Therapy Combination Increases Weight Loss Among Postmenopausal Women

Drug Topics

JULY 15, 2025

2 “These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” Regina Castaneda, MD, research fellow for the Division of Endocrinology at the Mayo Clinic, said in a release. said in a release.

Mayo Clinic

Mayo Clinic Specialty Pharmacies Compounding Independent Pharmacies

Belimumab Autoinjector Receives FDA Approval for Children With Active Lupus Nephritis

Pharmacy Times

JUNE 24, 2025

LN is a complication of SLE that occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and potential organ damage. Pharmacy Times. Mayo Clinic. It is the most common form of lupus. Additionally, this inflammation may harm the kidneys’ abilities to remove waste within the blood. McGovern G.

FDA

FDA Compounding Pharmacies Vaccines Immunization

FDA Approves Belimumab Autoinjection for Patients 5 and Older With Active Lupus Nephritis

Drug Topics

JUNE 24, 2025

1 “Having the Benlysta autoinjector provides a much-needed option that can help reduce the burden of frequent clinic visits for treatment and add greater flexibility for children and their families when considering continuity of care and routines of daily life." Mayo Clinic. REFERENCES 1. News release. June 24, 2025.

FDA

FDA Immunization Vaccines Mayo Clinic

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 19, 2025

1 "Immunotherapy given neoadjuvantly may not be the appropriate treatment strategy for patients with high fusion,” said Kaushal Parikh, MD, from Mayo Clinic. “In Mandatory ALK fusion testing should become part of the standard of care to better personalize treatments to a patient’s specific ALK variant.

Chemotherapy

Chemotherapy Compounding Pharmacies Hospitals Immunization

ASCO 2025: Cost-Effectiveness of Ribociclib in Early Breast Cancer

Pharmacy Times

JUNE 15, 2025

Following, HR+, HER2- early breast cancer is a common subtype where the cancer cells have estrogen and progesterone receptors but do not have excessive amounts of the HER2 protein, according to Mayo Clinic. Mayo Clinic. Clinicaltrials.gov: NCT05306340. Updated April 15, 2025. Accessed June 13, 2025. News release.

Mayo Clinic

Mayo Clinic Compounding Pharmacies Immunization Compounding

Underserved Patients Less Resilient During Pandemic Than Affluent Communities

Drug Topics

JULY 16, 2025

Mayo Clinic. Self-reported resilience during the COVID-19 pandemic. JAMA Netw Open. 2025;8(7):e2520360. doi:10.1001/jamanetworkopen.2025.20360 2025.20360 2. Resilience: Build skills to endure hardship. December 23, 2023. Accessed July 16, 2025. Nurture your resilience: bouncing back from difficult times. NIH News in Health. April 2022.

Specialty Pharmacies

Specialty Pharmacies Independent Pharmacies Compounding Vaccines

ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma

Pharmacy Times

JUNE 9, 2025

Mayo Clinic. Akkooi A, Mandala M, Kicinski M, Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation. J Clin Oncol. 43, 2025 (suppl 17; abstr LBA9500). doi:10.1200/JCO.2025.43.17_suppl.LBA9500.

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Compounding

Study Investigates Long-Term Cardiometabolic Impact of Early-Onset Obesity

Pharmacy Times

JULY 18, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. JAMA Netw Open. 2025;8(7):e2520011. doi:10.1001/jamanetworkopen.2025.20011 2025.20011 2. Long-term obesity and biological aging in young adults.

Compounding Pharmacies

Compounding Pharmacies Compounding Immunization Mayo Clinic

FDA Approves Expanded Labeling of Farapulse PFA System for Persistent Atrial Fibrillation

Pharmacy Times

JULY 14, 2025

Mayo Clinic. " 1 REFERENCES 1. Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System. News release. July 7, 2025. Accessed July 7, 2025. Atrial fibrillation. Accessed July 7, 2025. Boston Scientific. FARAPULSE™ Pulsed Field Ablation System. Accessed July 7, 2025.

Labelling

Labelling FDA Compounding Pharmacies Hospitals

Pharmacy Technician Pulse

TikTok Videos on IBD Provide Low Quality Information

Pharmacist-Led Interventions Show Promise in Improving COPD Outcomes

Trending Sources

Efficiency, Education, and Evolution: What’s Next for Pharmacy Practice?

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Pharmacists Take the Lead on Advanced Therapeutics

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Dual-Antigen Targeting in Myeloma: Improved Responses in Extramedullary Disease

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Tirzepatide, Hormone Therapy Combination Increases Weight Loss Among Postmenopausal Women

Belimumab Autoinjector Receives FDA Approval for Children With Active Lupus Nephritis

FDA Approves Belimumab Autoinjection for Patients 5 and Older With Active Lupus Nephritis

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

ASCO 2025: Cost-Effectiveness of Ribociclib in Early Breast Cancer

Underserved Patients Less Resilient During Pandemic Than Affluent Communities

ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma

Study Investigates Long-Term Cardiometabolic Impact of Early-Onset Obesity

FDA Approves Expanded Labeling of Farapulse PFA System for Persistent Atrial Fibrillation

Stay Connected